Has medical innovation reduced cancer mortality?
AbstractI analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during the period 2000-2009, by estimating difference-in-differences models using longitudinal (annual) data on about 60 cancer sites (breast, colon, etc.). The outcome measure used is not subject to lead-time bias. I control for mean age at diagnosis, the stage distribution of patients at time of diagnosis, and the sex and race of diagnosed patients. Under the assumption that there were no pre‐dated factors that drove both innovation and mortality and that there would have been parallel trends in mortality in the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age-adjusted cancer mortality rate during 2000-2009. Drug innovation and imaging innovation are estimated to have reduced the cancer mortality rate by 8.0% and 4.0%, respectively. The decline in incidence is estimated to have reduced the cancer mortality rate by 1.2%. The social value of the reductions in cancer mortality attributable to medical innovations has been enormous, and much greater than the cost of these innovations.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by National Bureau of Economic Research, Inc in its series NBER Working Papers with number 15880.
Date of creation: Apr 2010
Date of revision:
Publication status: published as “Has Medical Innovation Reduced Cancer Mortality?,” CESifo Economic Studies, published online 14 November 2013.
Note: HC HE PR
Contact details of provider:
Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Web page: http://www.nber.org
More information through EDIRC
Find related papers by JEL classification:
- C23 - Mathematical and Quantitative Methods - - Single Equation Models; Single Variables - - - Models with Panel Data; Spatio-temporal Models
- C33 - Mathematical and Quantitative Methods - - Multiple or Simultaneous Equation Models; Multiple Variables - - - Models with Panel Data; Spatio-temporal Models
- I12 - Health, Education, and Welfare - - Health - - - Health Production
- J1 - Labor and Demographic Economics - - Demographic Economics
- L64 - Industrial Organization - - Industry Studies: Manufacturing - - - Other Machinery; Business Equipment; Armaments
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
- O33 - Economic Development, Technological Change, and Growth - - Technological Change; Research and Development; Intellectual Property Rights - - - Technological Change: Choices and Consequences; Diffusion Processes
This paper has been announced in the following NEP Reports:
- NEP-ALL-2010-04-17 (All new papers)
- NEP-HEA-2010-04-17 (Health Economics)
- NEP-INO-2010-04-17 (Innovation)
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Frank R. Lichtenberg, 2012.
"Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-7,"
Springer Healthcare | Adis, vol. 30(3), pages 197-211.
- Frank Lichtenberg, 2012. "Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7," PharmacoEconomics, Springer, vol. 30(3), pages 197-211, March.
- Frank Lichtenberg, 2010. "The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France," CESifo Working Paper Series 3095, CESifo Group Munich.
- George Miller & Matthew Daly & Charles Roehrig, 2013. "Tradeoffs in cardiovascular disease prevention, treatment, and research," Health Care Management Science, Springer, vol. 16(2), pages 87-100, June.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().
If references are entirely missing, you can add them using this form.